ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling Pathway.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy marked by high morbidity, recurrence, and metastasis, with limited treatment options and poor prognosis. The challenge of early diagnosis and the inefficacy of current therapeutic strategies underscore the urgent need for novel biomarkers and therapeutic targets. RNA-binding proteins (RBPs) are emerging as critical regulators of post-transcriptional processes and are implicated in cancer progression. Here, the study identifies Staufen Double-Stranded RNA Binding Protein 2 (STAU2) as an oncogenic RBP with high expression in PDAC, which is significantly associated with metastasis. It is demonstrated that STAU2 directly binds and regulates cytoskeletal associated protein Palladin (PALLD) and mediates IQ motif containing

SUBMITTER: Ding J 

PROVIDER: S-EPMC12412546 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature